SONY vs SPRO
SONY (SONY) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
SONY (SONY) common stock.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
SONY does not have a complete income-statement cache yet.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
SONY currently screens at market cap $0. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the SONY and SPRO stock pages for the full models.
Not investment advice.